2 news items
23andMe Reports Third Quarter Fiscal 2024 Financial Results
GSK
ME
7 Feb 24
. "In Therapeutics, we presented encouraging Phase 1 data for 23ME-00610 at SITC, and are excited to move our novel 23ME-01473 program, a ULBP-6-targeting
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
ALEC
GSK
7 Feb 24
they are in their 40's and 50's with the disease running its course in 7-10 years.6 There are no U.S. Food and Drug Administration-approved
- Prev
- 1
- Next